免疫组织化学和骨髓形态学检测在非霍奇金淋巴瘤诊断和临床分期中的应用价值

Application Value of Immunohistochemistry and Bone Marrow Morphology Detection in the Diagnosis and Clinical Staging of Non-Hodgkin's Lymphoma

目的:分析免疫组织化学检测和骨髓形态学分析在非霍奇金淋巴瘤(NHL)诊断及临床分期中的应用价值。方法:选取本院64例非霍奇金淋巴瘤患者,通过单克隆相关抗体对其标本进行免疫组织化学检测,并进行骨髓形态学检查。结果:B细胞淋巴瘤相关抗体CD79a^+率为84.62%,CD20^+率为91.43%;T细胞淋巴瘤相关抗体CD45RO^+率为87.50%,CD3^+率为88.89%。10例(15.63%)发生淋巴瘤骨髓侵犯,8例(12.50%)患者进展为淋巴瘤-白血病期;20例(31.25%)患者淋巴瘤细胞低于5%。结论:免疫组织化学检测有助于明确非霍奇金淋巴瘤患者的T、B细胞淋巴瘤类型,而骨髓形态学分析能够明确非霍奇金淋巴瘤患者是否发生骨髓侵犯及进展为淋巴瘤-白血病期,其应用价值较高。

Objective： To investigate the application value of immunohistochemistry detection and bone marrow morphology analysis in the diagnosis and clinical staging of non-Hodgkin＇s lymphoma. Methods： Sixty - four cases of non-Hodgkin＇s lymphoma were selected in our hospital and the immunohistochemistry detection of pathologic specimens was perforemed by related monoclonal antibody and the bone marrow morphology was also examined. Results： The positive rate of antibody CD79a on B cell lymphoma was 84. 62%, and CD20 was 91.43% ; the positive rate of antibody CD45RO on T cell lymphoma was 87.50%, and 88.89% of CD3. The bone marrow involvement was found in 10 cases （ 15.63% ）, 8 cases（ 12. 50% ） progressed to lymphoma - leukemia period; lymphoma cells were lower than 5% in 20 cases （31.25%） . Conclusion：Immunohistochemistry detection can help to define the type of T or B cell lymphoma in patients with non-Hodgkin＇s lymphoma, the bone marrow morphology analysis can clear whether the patients with non-Hodgkin＇s lymphoma suffered from bone marrow involvement and whether developed to lymphoma - leukemia period. These methods possess more high value in clinical application.